OTC:PVCT | Free Cash Flow | PROVECTUS BIOPHARMACEUTICALS, INC.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2009-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$357,565.00
2025-12-31-$869,553.00
2025-03-31-$1.09M
2024-12-31-$912,008.00
2024-03-31-$1.04M
2023-12-31-$561,211.00
2023-03-31-$624,110.00
2022-12-31-$754,790.00
2022-03-31-$592,219.00
2021-12-31$1.62M
2021-03-31-$1.11M
2020-12-31-$957,563.00
2020-03-31-$716,322.00
2019-12-31-$1.14M
2019-03-31-$2.07M
2018-12-31-$810,283.00
2018-03-31-$1.74M
2017-12-31-$2.47M$4,761.00-$2.47M
2017-03-31-$3.23M
2016-12-31-$4.01M
2016-03-31-$8.05M
2015-12-31-$4.96M$0.00-$4.96M
2015-03-31-$4.19M
2014-12-31-$4.18M$0.00-$4.18M-511.79%
2014-03-31-$2.85M
2013-12-31-$2.18M$0.00-$2.18M
2013-03-31-$2.98M
2012-12-31-$3.33M$0.00-$3.33M
2012-03-31-$2.79M$15,885.00-$2.81M
2011-12-31-$3.94M$0.00-$3.94M
2011-03-31-$4.25M
2010-12-31-$3.98M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$3.33M
2024-12-31-$3.28M
2023-12-31-$2.57M
2022-12-31-$3.04M
2021-12-31-$1.01M
2020-12-31-$4.09M
2019-12-31-$6.19M
2018-12-31-$5.2M
2017-12-31-$10.35M$30,400.00-$10.38M
2016-12-31-$21.94M
2015-12-31-$17.41M$6,139.00-$17.42M
2014-12-31-$13.85M$70,590.00-$13.92M
2013-12-31-$9.89M$6,650.00-$9.9M
2012-12-31-$11.26M$15,885.00-$11.27M
2011-12-31-$17.2M$6,147.00-$17.21M
2010-12-31-$13.73M
2009-12-31-$8.6M$5,839.00-$8.6M